Search research articles
Contact Us
Filters
Showing results (11-20 of 28) with videos related to
Page
of 3
Sort By:
Rheumatology International
|
November 2, 2005
Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'
J L Hülsemann, J Ruof, H Zeidler, et al.
Zeitschrift Fur Rheumatologie
|
November 23, 2013
[Phase IV non-interventional studies in the treatment of rheumatoid arthritis with biologicals in Germany : real-life clinical practice data]
J Ruof, C Iking-Konert, S Simianer, et al.
Zeitschrift Fur Rheumatologie
|
April 27, 2002
[Health economics research in the area of chronic polyarthritis]
S Merkesdal, J Ruof, T Mittendorf, et al.
International Journal of Obesity (2005)
|
April 27, 2005
Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland
L A Lacey, A Wolf, D O'shea, et al.
Arthritis and Rheumatism
|
March 27, 2001
Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease
S Merkesdal, J Ruof, O Schöffski, et al.
International Journal of Obesity (2005)
|
March 2, 2005
Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland
J Ruof, A Golay, C Berne, et al.
Pharmacopsychiatry
|
July 4, 2001
Quality of partnership in patients with erectile dysfunction after sildenafil treatment
M J Müller, J Ruof, M Graf-Morgenstern, et al.
International Journal of Obesity (2005)
|
April 6, 2006
Content comparison of health status measures for obesity based on the international classification of functioning, disability and health
A Stucki, M Borchers, G Stucki, et al.
MMW Fortschritte Der Medizin
|
September 28, 2000
[Guidelines for lowering lipids are too infrequently observed. Results of a retrospective study of coronary heart disease patients]
G Klein, J Ruof, W März, et al.
Preventive Medicine
|
June 25, 2002
Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns
J Ruof, G Klein, W März, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 28) with videos related to
Sort By:
Page
of 3
Rheumatology International
|
November 2, 2005
Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'
J L Hülsemann, J Ruof, H Zeidler, et al.
Zeitschrift Fur Rheumatologie
|
November 23, 2013
[Phase IV non-interventional studies in the treatment of rheumatoid arthritis with biologicals in Germany : real-life clinical practice data]
J Ruof, C Iking-Konert, S Simianer, et al.
Zeitschrift Fur Rheumatologie
|
April 27, 2002
[Health economics research in the area of chronic polyarthritis]
S Merkesdal, J Ruof, T Mittendorf, et al.
International Journal of Obesity (2005)
|
April 27, 2005
Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland
L A Lacey, A Wolf, D O'shea, et al.
Arthritis and Rheumatism
|
March 27, 2001
Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease
S Merkesdal, J Ruof, O Schöffski, et al.
International Journal of Obesity (2005)
|
March 2, 2005
Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland
J Ruof, A Golay, C Berne, et al.
Pharmacopsychiatry
|
July 4, 2001
Quality of partnership in patients with erectile dysfunction after sildenafil treatment
M J Müller, J Ruof, M Graf-Morgenstern, et al.
International Journal of Obesity (2005)
|
April 6, 2006
Content comparison of health status measures for obesity based on the international classification of functioning, disability and health
A Stucki, M Borchers, G Stucki, et al.
MMW Fortschritte Der Medizin
|
September 28, 2000
[Guidelines for lowering lipids are too infrequently observed. Results of a retrospective study of coronary heart disease patients]
G Klein, J Ruof, W März, et al.
Preventive Medicine
|
June 25, 2002
Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns
J Ruof, G Klein, W März, et al.
Page
of 3